Merck to acquire San Diego biotech company Prometheus Biosciences for $10.8 billion
April 17, 2023 at 09:02 AM EDT
Under the terms of the deal announced Sunday, Merck (NYSE: MRK) will acquire Prometheus Biosciences (NASDAQ: RXDX) for $200 per share in cash.
